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Members of the transforming growth factor-b (TGF-b) family regulate a wide range of biological processes including cell proliferation,
migration, differentiation, apoptosis, and extracellular matrix deposition. Resistance to TGF-b-mediated tumour suppressor function
in human lung cancer may occur through the loss of type II receptor (TbRII) expression. In this study, we investigated the expression
pattern of TbRII in human lung cancer tissues by RT–PCR and Western blot analyses. We observed downregulation of TbRII in 30
out of 46 NSCLC samples (65%) by semiquantitative RT–PCR. Western blot analyses with tumour lysates showed reduced
expression of TbRII in 77% cases. We also determined the effect of TbRII expression in lung adenocarcinoma cell line (VMRC-LCD)
that is not responsive to TGF-b due to lack of TbRII expression. Stable expression of TbRII in these cells restored TGF-b-mediated
effects including Smad2/3 and Smad4 complex formation, TGF-b-responsive reporter gene activation, inhibition of cell proliferation
and increased apoptosis. Clones expressing TbRII showed reduced colony formation in soft-agarose assay and significantly reduced
tumorigenicity in athymic nude mice. Therefore, these results suggest that reestablishment of TGF-b signalling in TbRII null cells by
stable expression of TbRII can reverse malignant behaviour of cells and loss of TbRII expression may be involved in lung tumour
progression.
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Transforming growth factor-b (TGF-b) belongs to a superfamily
of structurally related polypeptides that are involved in
various biological processes, including cell growth, differentiation,
angiogenesis, apoptosis, and extracellular matrix remodelling
(Massague, 1998). The multifunctional effects of TGF-b in cellular
actions occur by binding to its receptors with intrinsic serine/
threonine kinase activity. Sequence comparisons indicate that
these receptors fall into two subgroups, designated as type I (TbRI)
and type II (TbRII) serine–threonine kinase receptors. Trans-
forming growth factor-b initiate signals by binding to TbRII
and stabilises the heteromeric complex with TbRI, and as a result,
TbRI is transphosphorylated within a glycine–serine-rich domain
(GS-domain). The activated TbRI then propagates the signals to
intracellular signal mediators including Smads (Engel et al, 1998;
Massague and Wotton, 2000).
Smad proteins are classified according to their structure and
function in signalling by TGF-b family members (Attisano and
Wrana, 1998). They are characterised by homologous regions at
their N- and C-termini known as Mad homology (MH-1 and MH-
2) domains, respectively. A divergent linker region separates these
domains. Both structural and functional differences provide the
basis for a division of the Smads into three groups: receptor
regulated (R-Smad), common-mediator, and inhibitory Smads. R-
Smads including Smad1, 2, 3, 5, 8, and 9, act as direct substrates of
specific type I receptors and are activated by phosphorylation of
serine residues at the carboxyl terminus. Thus, Smad2 and Smad3
mediate signalling by TGF-b and activin, while Smad1 and
presumably Smad5, Smad8, and Smad9 are similarly modified
through bone morphogenetic protein (BMP) exposure (Engel et al,
1998). Transforming growth factor-b/activin receptor-phosphory-
lated Smads (R-Smads) oligomerise with the common mediator
Smad4 (Co-Smad), and after nuclear import, they regulate gene
expression positively or negatively by binding to DNA or by
interacting with transcription factors (Shi and Massague, 2003). A
distinct class of distantly related Smads, including Smad6 and
Smad7, has been identified as inhibitors of these signalling
pathways. Smad7 forms stable associations with activated type I
receptors, thereby preventing R-Smads from binding to and being
phosphorylated by these receptors (Hayashi et al, 1997; Nakao
et al, 1997). Thus, Smad7 inhibits TGF-b, activin, and BMP
signalling. Recently, we have cloned a novel WD40 domain-
containing protein called STRAP that associates with both TbRI
and TbRII and is involved in the negative regulation of
TGF-b signalling (Datta et al, 1998). STRAP synergises with
Smad7, but not with Smad6, in the inhibition of TGF-b-induced
transcriptional responses. STRAP associates with Smad7, recruits
it from the cytosol to the activated TbRI, and stabilises the
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sheteromeric complex, thereby assisting Smad7 in preventing
Smad2 and Smad3 activation by the receptor complex (Datta and
Moses, 2000). A distinct mechanism of inhibition for Smad6 and
its primary role in regulating BMP signals have been proposed
(Hata et al, 1998; Ishisaki et al, 1999). The expression of Smad6
and Smad7 is increased in response to BMP, activin, and TGF-b,
suggesting a negative feedback of these pathways (Nakao et al,
1997; Ishisaki et al, 1999).
Perhaps one of the most important biological effects of TGF-b is
its ability to inhibit proliferation of many cell types, including
most epithelial cells (Moses et al, 1990). As a result, the
mechanism(s) of TGF-b growth inhibition has been the subject
of intense investigation over the past decade. Transforming growth
factor-b inhibits progression of cells from G1 into the S phase of
the cell cycle (Pietenpol et al, 1990; Howe et al, 1991). Cell cycle
progression is mostly governed by Cdks, which are activated by
Cyclins binding and inhibited by the Cdk inhibitors. Although
there is not much data linking the known TGF-b-signalling
pathways with the regulators of cell cycle progression implicated in
TGF-b-induced growth arrest. Several lines of evidence suggest
that Smad signalling is functionally connected directly or
indirectly in suppressing the growth of epithelial cells. The
primary event that initiates the TGF-b-induced growth arrest
may be associated with increased expression of p15
INK4B, p21
Cip1,
and suppression of c-Myc expression. Deregulation of Cdk
inhibitors may contribute to TGF-b resistance in cancer. Loss of
p21
Cip1 has been observed in advanced breast cancers in association
with a poor patient prognosis (Jiang et al, 1997). In epithelial cells
from the skin, lung, and breast, TGF-b rapidly elevates expression
of the Cdk4/6 inhibitor p15
INK4B (Hannon and Beach, 1994). In
keratinocytes, colon and ovarian epithelial cells, TGF-b elevates the
expression of p21
Cip1 (Elbendary et al, 1994; Datto et al, 1995).
Smad signalling is required for TGF-b-mediated induction of
p15
INK4B (Feng et al, 2000), and p21
Cip1 (Pardali et al, 2000).
Transforming growth factor-b stimulation of epithelial cells induces
the formation of a Smad complex that specifically recognises a
TGF-b-inhibitory element in the c-Myc promoter, and this response
may be critical for TGF-b-induced c-Myc downregulation and
growth arrest (Chen et al, 2001). Dominant-negative Smad3 (Liu
et al, 1997) or the inhibitory Smad, Smad7 (Itoh et al, 1998) blocks
TGF-b-induced growth inhibition in epithelial cells.
Cell growth is modulated by positive and negative signals, and
loss of negative growth constraints may contribute to oncogenic
processes. Such perturbations may occur as a consequence of the
loss of the tumour suppressor functions of TGF-b. One of the
physiological roles of the TGF-b-signalling pathway is to provide
protection against malignant transformation. Loss of TGF-b
receptor expression has been reported in several tumours,
including colon cancer (Markowitz et al, 1995), breast cancer
(Sun et al, 1994), prostrate cancer (Guo and Kyprianou, 1998), and
TGF-b expression is elevated in these tumours. Resistance to TGF-
b in lung cancer may occur through several mechanisms that
involve functional alteration of signalling molecules. A recent
study has demonstrated that most lung cancer cell lines have lost
the growth-inhibitory response to TGF-b signal (Osada et al, 2001).
It has been suggested that TGF-b resistance stemming from
inactivation of TbRII could be a multiple process involving both
genetic and epigenetic events. Moreover, extensive analyses found
that mutations within the coding sequence of the TbRII gene are
rare in NSCLC. Replication error phenotype, a high incidence of
mutation in poly-adenosine (poly-A) tract of the TbRII gene was
found leading to loss of TbRII in colon and gastric cancer
(Markowitz et al, 1995). Therefore, mutation in the poly-A tract or
truncation in the kinase domain of TbRII is infrequent in lung
cancer. Mutations of Smad2 and Smad4 genes have been found in a
limited fraction of lung cancers (5–10%) (Nagatake et al, 1996;
Uchida et al, 1996). Two previous reports have shown (Hougaard
et al, 1999; Osada et al, 2001) that four out of 33 lung cancer cell
lines are responsive to TGF-b-induced growth inhibition and 29
cell lines are unresponsive to TGF-b. However, among these
unresponsive cell lines, 21 cell lines show either no expression or
weak expression of TbRII. Therefore, downregulation of TbRII can
explain TGF-b unresponsiveness in certain fraction of lung
cancers. A recent study has suggested that impairment of TGF-b
signalling may contribute to tumour progression by cell prolifera-
tion rather than by modulation of angiogenesis (Park et al, 2002).
These findings suggest that cancer cells could result in escape from
autocrine growth inhibitory effect of TGF-b due to the loss of
TbRII. A correlation between diminished expression of TbRII in
breast cancer cells and enhanced in vivo malignant behaviour has
been observed in studies based on patient specimens and an
established cell line (Gobbi et al, 2000), suggesting that attenuation
of the growth inhibitory TGF-b autocrine loop in breast cancers
worsens clinical outcome. However, little is known about the
TbRII status in lung cancer and whether restoring TGF-b
signalling by the introduction of functional TGF-b type II receptor
alters tumorigenicity in TGF-b unresponsive lung cancer cell lines
that do not express the type II receptor. In the present study, we
have carried out RT–PCR and Western blot analyses with human
lung tumour tissues to analyse the expression pattern of TbRII for
the first time. Out of 46 lung tumour samples analysed by RT–
PCR, squamous cell carcinoma (80%), adenocarcinoma (42%), and
large cell carcinoma (72%) show downregulation or loss of TbRII,
and Western blot analyses suggest reduced expression of TbRII in
77% of lung tumour samples. We have determined the effects of
stable expression of TbRII in TGF-b-unresponsive human lung
tumour-derived VMRC-LCD cells lacking TbRII expression. TbRII
expression restores TGF-b downstream signalling as determined
by the induction of Smad2/3 and Smad4 complex formation, TGF-
b-responsive reporter gene activation, inhibition of cell prolifera-
tion and induction of apoptosis. We also show that clones
expressing TbRII reduce colony formation in soft-agarose assay
and tumorigenicity in athymic nude mice. Therefore, our data
support the notion that impairment of TGF-b tumour suppressor
function may contribute to lung tumour progression.
MATERIALS AND METHODS
Cell culture and biological reagents
Fresh lung tumour and the corresponding normal tissue specimens
were collected from 46 patients. These patients had received
neither radiotherapy nor chemotherapy before surgery. They
underwent pulmonary resection for primary NSCLC at Vanderbilt
University School of Medicine Hospital. Informed consent was
received and the project was approved by the local Institutional
Review Board. VMRC-LCD parental cell line (human lung adeno-
carcinoma derived) was maintained in RPMI medium supplemen-
ted with 10% fetal bovine serum (FBS). Vector control and TbRII
stable clones were maintained in Geneticin (G418 sulfate; Life
Technologies Inc., Carlsbad, CA) selection at 400mgml
 1. All cell
lines were maintained at 371C in presence of 5% CO2 in a humidi-
fied incubator. Transient transfections were performed using
lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s specifications. Anti-Smad2, anti-Smad3 (Zymed
Laboratories Inc., Sanfrancisco, CA), anti-p21
Cip1, anti-Smad4
antibody (Santa Cruz Biotechnology Inc., Santacruz, CA), anti-
phospo-Smad2 antibody (Cell Signalling, Beverly, MA) and mouse
anti-b-actin antibody (Sigma Biochemicals, St Louis, MO) were
used in this study. Antiphospho-Smad3 antibody was a generous
gift from Dr Edward B. Leof (Mayo Clinic, Rochester, MN). The
TGF-b receptor kinase inhibitor, SB-431542 was kindly provided
by Dr. Nicholas J. Laping from the Glaxo SmithKline, King of
Prussia, PA, USA. SB-431542 was also purchased from Tocris
Cookson Inc., Ellisville, MO, USA.
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sRNA extraction and reverse transcription (RT)-PCR
analysis
Total RNA from the tissue specimens was isolated by using Tripure
RNA Purification Kit (Roche Applied Science, Indianapolis, IN).
RNA quality and concentration were estimated spectrophotome-
trically at 260nm. RT–PCR was performed using SUPERSCRIPT II
Kit RETROscript
TM (Ambion Inc., Austin, TX). The cDNA was
synthesised from total RNA (1mg) using oligo(dT)15 primer and
reverse transcriptase. The TbRII (493bp) gene fragment was
amplified by using the following primers; 50-gcacgttcagaagtcggtta-
30 (forward) and 50-gcggtagcagtagaagatga-30 (reverse). The primer
sequences for GAPDH fragment (600bp) were 50-ccacccatgg
caaattccatggca-30 (forward) and 50-tctagacggcaggtcaggtccacc-30
(reverse). PCR amplification was carried out using 2ml of the
above RT reaction mixture and 1  PCR buffer, 1.5mM MgCl2,2U
of Taq DNA polymerase, and 10nm of each Primer. After initial
denaturation at 941C for 3min, amplification conditions were as
follows: 30 cycles of 941C for 30s, 551C for 30s, and 721C for 1min;
followed by a final 5min extension at 721C. The RT–PCR products
were separated on a 1.5% agarose gel.
Transcriptional response assay
VMRC-LCD cells were transiently transfected with CMV-b-gal, and
p3TP-Lux, or (CAGA)9 MLP-Luc or p21
Cip1-Luc reporter plasmids.
Transfected cells were incubated in 0.2% FBS in presence or
absence of 2 or 5ngml
 1 of TGF-b1 for 22h. Cell lysates were used
to measure both luciferase and b-gal activities, and the normalised
luciferase activity was presented.
Immunoprecipitation and Western blot analyses
VMRC-LCD cells were serum starved for 2h and treated in the
presence or absence of 5ngml
 1 of TGF-b for 90min. Cells were
lysed and equal amount of each protein lysate was incubated with
both anti-Smad2 and anti-Smad3 polyclonal antibodies for 2h at
41C, followed by incubation with 20ml of protein G-Sepharose
beads (Sigma Biochemicals, St Louis, MO) for 1h. The immune
complexes were analysed by Western blotting with mouse anti-
Smad4 antibody. For other Western blots, extracts were prepared
from VMRC-LCD cells treated in presence or absence of TGF-b at
different time intervals indicated in figure legends.
[
3H]-Thymidine incorporation assay
VMRC-LCD cells were treated in the presence or absence of TGF-
b1 for 36h in 10% FBS medium. 4mCiwell
 1 [
3H]-thymidine
(NEN, Boston, MA) was added in each well for an additional 4h.
Cells were then fixed in 10% cold trichloroacetic acid (TCA),
washed, and lysed in 0.2 N NaOH. Radioactivity incorporated into
TCA-insoluble [
3H]-thymidine was measured by scintillation
counting and presented.
Cell proliferation assay
VMRC-LCD cells were seeded into 12-well plates. Cells were then
treated in the presence or absence of TGF-b (0.5 or 5ngml
 1) for a
total of 5 days. Transforming growth factor-b-containing media
was replaced every other day. Cells were counted after 5 days and
the average cell numbers from triplicate measurements were
plotted.
Cell death ELISA
VMRC-LCD cells (2 10
4 cellswell
 1) were seeded into 12-well
plates and allowed to attach for 20h. Cells were serum starved for
20h and then treated in the presence or absence of 5 or 10ngml
 1
of TGF-b1 for 24h. Cells (floating and adherent) were lysed in
200ml of lysis buffer. Apoptosis in these cells was quantified by
using a cell-death detection ELISA kit (Roche Molecular Biochem-
icals, Laval, Quebec, Canada) according to the manufacturer’s
instructions. This quantitative sandwich enzyme immunoassay
specifically measures the histone region (H1, H2A, H2B, H3, and
H4) of mono- and oligonucleosomes that are released during
apoptosis. Photometric development was monitored kinetically by
reading the plate at 405nm at 5-min intervals by using a
THERMOmax microplate reader (Molecular Devices Corp., Menlo
Park, CA, USA). All data points were assessed in triplicate.
Soft-agarose assay
Soft-agarose assays were performed to compare the clonogenic
potential of control and TbRII-transfected cells. In all, 5 10
4 cells
from each pool were suspended in 1ml of 0.4% sea plaque agarose
containing 10% FBS medium and then plated on the top of 1ml of
semisolidified 0.8% agarose in the same medium in 35mm plates.
For each parental, vector control, and TbRII clones, triplicate wells
were plated. Plates were incubated for 2 weeks at 371C in the
presence of 5% CO2 in a humidified incubator. Colonies grown on
soft agarose were counted by automated colony counter.
Tumorigenicity study
Cells from exponential cultures of VMRC-LCD (5 10
6 cells) were
inoculated subcutaneously behind the anterior fore limb of
6-week-old athymic nude mice. Mice were maintained in a
pathogen-free facility and tumours were measured two times in a
week. Growth curves for xenografts were determined by exter-
nally measuring tumours in two dimensions using a slide
caliper. Tumour volume was determined from the equation: V¼
(L W
2) 0.5, where L is length and W is width of the tumour.
Growth curves for tumours were plotted from the mean
volume7s.d. of tumours from six mice. The use of these mice in
research was approved by Vanderbilt University Institutional
Animal Care and Use Committee.
RESULTS
Downregulation of TbRII in non-small-cell lung cancers
(NSCLC)
Reduced expression of TGF-b receptors is known to be associated
with unresponsiveness to TGF-b-mediated growth inhibitory
function and may be involved in tumour progression. To verify
whether TbRII level is downregulated in human lung tumours, we
analysed for TbRII expression by RT–PCR using RNA samples
from 46 lung tumour specimens (20 squamous cell carcinoma,
19 adeno carcinoma, and seven large cell carcinoma) (Figure 1A).
The TbRII expression was found to be decreased in 80% of
squamous cell carcinoma, 42% adenocarcinoma, and 72% large
cell carcinoma. Since we observed reduced TbRII mRNA expres-
sion in NSCLC, we tested the expression of TbRII protein in lysates
made from tumour specimens by Western blot analysis. Out of
22 lung tumour samples (including squamous, adeno, and large
cell carcinoma) analysed with corresponding control, 17 tumours
(77%) showed reduced TbRII protein level (Figure 1B). 10
specimens showed almost no expression of TbRII. These results
suggest that the expression of TbRII is reduced in majority of
NSCLC patients.
Stable expression of TbRII in VMRC-LCD cells induces
Smad2/Smad3 and Smad4 complex formation
In order to express TbRII in VMRC-LCD lung adenocarcinoma
cells lacking its expression, wild-type TbRII was transfected and
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scells were selected with G418 to generate stable clonal cell lines.
Quantitative RT–PCR was performed to test and to compare the
expression of TbRII mRNA in stable VMRC-LCD cells and in lung
adenocarcinoma cells (A549) (Figure 2A). These data suggest the
physiological level of expression of TbRII in VMRC-LCD cells. We
also tested expression of the protein by Western blot analyses
(Figure 2B). Three clones that expressed high levels of TbRII
(TbRII #10, TbRII #13 and TbRII #17) were selected for further
experiments. To test whether overexpressed TbRII is functional,
we first analysed the phosphorylation of endogenous-positive
regulatory Smads, Smad2 and Smad3. Parental cells, two vector
control clones, and three TbRII clones were treated with TGF-b
for 90min and cell lysates were subjected to Western blot analyses
by antiphospho-Smad2 and antiphospho-Smad3 antibodies. Phos-
phorylation of Smad2 and Smad3 (Figure 3A, first and third panel)
was found to be increased in TbRII stable clones although the
expressions of these proteins were unchanged. To test whether
stable expression of TbRII can restore the complex formation bet-
ween Smad2/Smad3 and Smad4 in vivo, we performed immuno-
precipitation experiments after treating TbRII clones, vector
clones, and parental cells with TGF-b for 90min. Equal amounts
of cell lysates were used for immunoprecipitation with both anti-
Smad2 and anti-Smad3 antibodies. The immune complexes were
analysed by Western blot with anti-Smad4 monoclonal antibody.
Transforming growth factor-b-induced heteromeric complex
formation between Smad2/Smad3 and Smad4 was increased in
TbRII-expressing clones as compared to parental and vector
control clones (Figure 3B). To confirm the TGF-b downstream
signalling is intact in VMRC-LCD cells, we performed transcrip-
tional assays using TGF-b-responsive reporter (CAGA)9 MLP-Luc.
We observed an increase in transcriptional activity by transfection
of TbRII and a further strong induction in response to TGF-b.
Transfection of constitutively active TGF-b type I receptor
(T204D) (act-TbRI) alone induced the reporter activity in
VMRC-LCD cells (Figure 3C), because act-TbRI does not require
TGF-b and TbRII for downstream signalling. These results suggest
that VMRC-LCD cells lack TbRII expression and the downstream
signalling cascade is intact. Together, stable expression of TbRII
restores TGF-b/Smad signalling in VMRC-LCD cells.
TbRII expression restores TGF-b-induced transcriptional
responses and p21
Cip1 expression
To explore the functional significance of TbRII expression in
VMRC-LCD cells, we focused our analyses on TGF-b-induced
transcriptional responses. We used two TGF-b-responsive repor-
ters. The first reporter (CAGA)9 MLP-Luc contains multiple
Smad3/Smad4-binding CAGA boxes upstream of a minimal
adenovirus major late promoter. The second reporter p3TP-Lux
containing element from the PAI-1 promoter has both Smad- and
N    T1    T2 T3   T4   T5   T6   T7   T8   T9  T10 T11 T12 T13 T14 T15 T16
T33 T34 T35 T36 T37 T38  T39 T40 T41 T42 T43 T44  T45 T46  N
T17 T18 T19 T20 T21 T22 T23 T24 T25 T26 T27  T28 T29 T30 T31 T32 N
T RII
GAPDH
T RII
GAPDH
T RII
GAPDH
N = normal
T = tumour
**** * * * * * * *
NN T N T N T N T N T N
T RII
 -Actin
NTNTNTNTNT NTNTNTNTNT **** **
T RII
 -Actin
T T NT NT NT NT NT
A
B
Figure 1 Downregulation of TbRII mRNA in lung tumours as determined by RT–PCR. (A) Total RNA extracted from human lung tumour tissues were
reverse transcribed, and the resulting cDNA was analysed by PCR to test TbRII expression. The integrity and equal loading of the RT products was assessed
by analysing hGAPDH expression. (B) Western blot analysis of TbRII protein in lung tumour and corresponding normal lung tissues. Equal amount of lysates
were resolved in SDS–PAGE and analysed by Western blotting using antibody against TbRII. Equal loading was verified by Western blotting using mouse
monoclonal anti-b-actin antibody. Tumours with asterisk showed reduced expression of TbRII.
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sAp1-binding elements. Stable TbRII clones showed higher reporter
activity in response to TGF-b, whereas parental and vector clones
did not show any significant response to TGF-b (Figure 4A).
Similarly, (CAGA)9 MLP-Luc reporter activity was strongly
induced in response to TGF-b in TbRII-expressing clones when
compared with parental and vector control (Figure 4B). Interest-
ingly, both reporters were induced significantly in TbRII clones
without TGF-b treatment as compared to parental and vector
control cells. In an attempt to determine why TbRII expression
alone induces transcriptional activation, we have performed
experiment to block endogenous and exogenous TGF-b effect by
a TGF-b receptor kinase inhibitor (SB-431542) (Halder et al, 2005).
VMRC-LCD parental cells were transiently cotransfected with
TGF-b-responsive reporter (CAGA)9 MLP-Luc and TbRII. Cells
were treated with TGF-b (5ngml
 1) in the presence or absence of
SB-431542 for 22h. We observed an increase in transcriptional
response by TbRII alone. This effect was completely blocked by
SB-431542 treatment (Figure 4C) suggesting that expression of
TbRII can restore signalling induced by endogenous TGF-b.
VMRC-LCD cell line has been shown to secret significant amount
of functional TGF-b (Halder et al, 2005). As expected, this
inhibitor also blocks the effect of exogenous TGF-b. To compare
how well the restoration of TGF-b signalling has worked, we
performed reporter assay using VMRC-LCD cells stably expressing
TbRII and TGF-b responsive lung adenocarcinoma cells A549 that
express TbRII. We have observed four- and seven-fold induction
in TGF-b-induced transcription in VMRC-LCD cells expressing
TbRII and in A549 cells (Figure 4D), respectively. These results
coupled with the Figure 2A suggest that TGF-b signalling has been
restored in VMRC-LCD cells by the expression of physiological
level of functional TbRII. To investigate the effect of TbRII
expression on natural promoter, we performed transient trans-
fection assays with a reporter plasmid containing the luciferase
gene under the control of the TGF-b-inducible p21
Cip1 gene
promoter. This reporter was induced in TbRII clones in response
to TGF-b but not in parental or vector clones, where the cells do
not have TbRII expression (Figure 4E). To test whether restoration
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Figure 2 Stable VMRC-LCD cells expressing TbRII. (A) The VMRC-
LCD cells were transfected with TbRII-pcDNA3 or empty pcDNA3 vector
(Invitrogen) and selected with G418 for 2 weeks to establish the stable
clones. In all, 20ng of total RNA was used for TbRII stable VMRC-LCD
clones, vector clones and parental cells. Quantitative real-time RT–PCR
was performed to determine the relative mRNA expression level of each
TbRII stable clones. Dilutions of RNA isolated from A549 cells was used as
standards for comparison. The stable expression of TbRII mRNA in VMRC-
LCD clones were compared with the endogenous TbRII expression in
A549 cells. (B) Cell lysates from parental, vector clone, and stable TbRII
clones were subjected to immunoblotting with anti-TbRII antibody.
Expression of TbRII protein in individual clones is shown. Equal amount
of protein loading was verified by immunoblotting the membrane with anti-
b-actin antibody.
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Figure 3 Stable expression of TbRII in VMRC-LCD cells restores TGF-b-induced phosphorylation of Smad2 and Smad3 and complex formation with
Smad4. (A) Parental cells, vector control and stable TbRII clones were preincubated for 2h in serum-free medium and then treated with TGF-b1( 5n gm l
 1)
for 90min. Cell lysates were subjected to immunoblotting with antiphospho Smad2, anti-Smad2, antiphospho Smad3, anti-Smad3, and anti-Smad4
antibodies. Equal amount of protein loading was tested by immunoblotting the membrane with anti-b-actin antibody. (B) Parental cells, vector control, and
stable TbRII clones were treated with TGF-b as above. Equal amount of cell lysates were subjected to immunoprecipitation with anti-Smad2 and anti-Smad3
polyclonal antibodies and the immunoprecipitates were analysed by immunoblotting with anti-Smad4 antibodies. (C) VMRC-LCD parental cells were
transiently transfected with (CAGA)9 MLP-Luc, and CMV-b-gal, TbRII or act-TbRI (T204D) expression plasmids. Cells were treated with 5ngml
 1 TGF-b
for 22h. Luciferase activity was normalised to b-gal activity, and the relative luciferase activity was expressed as the mean7s.d. of triplicate measurements.
These experiments were repeated at least three times. *Po0.001 for all groups in a multiple comparison test with Bonferroni adjustments after rank
transforming the data.
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expression, we analysed the expression of p21
Cip1 protein in
parental, vector control, and three stable TbRII clones in response
to TGF-b at different time points. The cell lysates were subjected
to Western blot analyses using anti-p21
Cip1 antibody (Figure 4F).
Parental and vector clones did not show any induction. How-
ever, TGF-b-induced p21
Cip1 protein expression significantly in
all three stable TbRII clones, and its expression is maintained
up to 16h after the treatment. These results show that VMRC-LCD
cells are unresponsive to TGF-b due to the lack of TbRII
expression, and re-expression of TbRII makes these cells
responsive to TGF-b.
Expression of TbRII in VMRC-LCD cells induces
TGF-b-mediated growth inhibition
One of the most important biological effects of TGF-b is its ability
to inhibit proliferation of many cell types. To determine the effect
of TbRII expression on TGF-b-induced growth inhibition, we first
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3H]-thymidine incorporation assay using control cells
and TbRII-expressing clones. DNA synthesis in TbRII clones is
decreased in response to TGF-b in a dose-dependent manner.
However, we did not observe significant change in thymidine
incorporation in parental and vector control cells in response to
TGF-b (Figure 5A). To compare the growth inhibitory effect of
TGF-b on DNA synthesis between stable TbRII-expressing VMRC-
LCD clone and A549 cells with endogenous TbRII expression, we
Figure 4 Restoration of TGF-b-induced transcriptional responses by stable expression of TbRII. Parental, vector control, and TbRII stable clones were
transiently cotransfected with CMV-b-Gal, p3TP-Lux (A) or (CAGA)9 MLP-Luc (B) plasmids. At 20h after transfection, cells were treated with TGF-b1( 2
or 5ngml
 1) for an additional 22h in low serum (0.2% FBS)-containing medium. Luciferase activity was normalised to b-gal activity, and the relative luciferase
activity was expressed as the mean7s.d. of triplicate measurements. *Po0.0001 for all groups in (A) and (B) in a linear mixed effect model on the log-
transformed data. (C) VMRC-LCD parental cells were transfected with CMV-b-Gal, CMV-TbRII, and (CAGA)9 MLP-Luc plasmids. At 20h after transfection,
cells were treated with 5ngml
 1 TGF-b in the presence or absence of SB-431542 (10mM) for an additional 22h in low serum (0.2% FBS)-containing
medium. Luciferase activity was normalised to b-gal activity, and the relative luciferase activity was expressed as the mean7s.d. of triplicate measurements.
(D) Stable TbRII clone and A549 parental cells were transiently cotransfected with CMV-b-Gal and (CAGA)9 MLP-Luc plasmids. Cells were treated with
TGF-b1( 5n gm l
 1) for 22h as above. Luciferase activity was normalised to b-gal activity, and the relative luciferase activity was expressed as the mean7s.d. of
triplicate measurements. **Po0.05, *Po0.005 for all groups in (C) and (D) in a multiple comparison test with Bonferroni adjustments after rank transforming
the data. (E) Cells were transiently transfected with CMV-b-gal and p21
Cip1-Luc plasmid and treated with 2 or 5ngml
 1 of TGF-b1 for 22h. Luciferase activity
was normalised to b-gal activity, and the relative luciferase activity was expressed as the mean7s.d. of triplicate measurements. *Po0.001 for all groups in a
linear mixed effect model on the log-transformed data. (F) Parental, vector control, and TbRII stable clones were serum starved for 16h and treated with
5ngml
 1 of TGF-b1 for different time points. Cell lysates were analysed by Western blotting with anti-p21
Cip1 antibody (Santa Cruz Biotechnology). Equal
amount of protein loading was verified by Western blotting with anti-b-actin antibody. Each experiment was repeated three times with similar results.
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Figure 5 Expression of TbRII induces TGF-b-mediated growth inhibition. Thymidine Incorporation Assay. (A) 30000cellswell
 1 of VMRC-LCD in 24-
well plate were treated with increasing doses of TGF-b in presence of 10% FBS-containing medium for 36h. 4mCiwell
 1 [
3H]-thymidine (NEN) was added
in each well for an additional 4h. Cells were then fixed, lysed, and the radioactivity incorporated was counted. Radioactivity incorporated without TGF-b
treatment is considered as 100%, and the results are expressed as the mean7s.d. for triplicate measurements. (B) Stable TbRII clone and A549 cells were
plated as above and treated with TGF-b for 36h. Cells were processed as above and the radioactivity incorporated was counted. Radioactivity incorporated
without TGF-b treatment is considered as 100%, and the results are expressed as the mean7s.d. for triplicate measurements. *Po0.05 for all groups in (A)
and (B) were compared by Wilcoxon’s test. (C) Cell counting assay. In all, 8 10
3 cells from parental, vector control, and stable TbRII clones were seeded
into each well of 12-well plate and then treated with TGF-b (0.5 or 5ngml
 1) in 10% FBS-containing medium. Cells were counted after 5 days and plotted.
Each data point is expressed as the mean7s.d. of triplicate measurements. Each experiment was repeated three times with similar results. (D) VMRC-LCD
parental, vector control, and TbRII stable clones were treated with 5ngml
 1 TGFb in the presence or absence of SB-431542 (10mM) for 5 days. Cells were
counted and the cell numbers were plotted. Individual data points are the mean7s.d. of triplicate determinations. *Po0.005 for all groups in (C) and (D)i n
a linear mixed effect model on the log-transformed data.
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incorporation by TGF-b was 30% in VMRC-LCD stable cells and
25% in A549 cells (Figure 5B). These results suggest that both cell
lines has comparable inhibitory effect on thymidine incorporation
in response to TGF-b. We further tested the effect of TbRII
expression on cell proliferation by cell counting assays. Parental
cells, vector and TbRII clones were treated with TGF-b and the
cells were counted after 5 days. Transforming growth factor-b
treatment did not affect the growth of both parental and vector
control cells, whereas the growth of stable TbRII-expressing cells
were significantly inhibited by TGF-b treatment (Figure 5C).
Interestingly, the growth of TbRII clones were inhibited in absence
of TGF-b and this could be due to endogenous TGF-b secretion. To
confirm the inhibitory role of endogenous TGF-b on cell growth in
TbRII stable cells, we treated the VMRC-LCD parental, vector
clones and TbRII clones with TRKI (SB-431542) in the presence or
absence of TGF-b. Growth of parental cells and vector clones was
not affected by either TGF-b or the inhibitor. However, growth
inhibition induced by endogenous or exogenous TGF-b was
significantly blocked by the inhibitor in stable TbRII clones
(Figure 5D) suggesting the reestablishment of autocrine endogen-
ous TGF-b signalling in these cells. These results suggest that loss
of TbRII is important for VMRC-LCD cells to be resistant to TGF-
b-induced growth suppression.
TGF-b induces apoptosis in VMRC-LCD cells expressing
TbRII
TGF-b is known to induce apoptosis depending on cell types that
might contribute to TGF-b-mediated tumour suppressor function.
To evaluate the role of stable expression of TbRII in apoptosis in
VMRC-LCD cells, we performed a quantitative cell death ELISA
assay using VMRC-LCD cells and stable TbRII clones in the
presence or absence of TGF-b.T bRII stable clones showed
significant increase in apoptosis in a dose-dependent manner
(Figure 6). However, parental and vector control cells did not show
any change in apoptosis in response to TGF-b. Sodium butyrate
induced apoptosis in both control and TbRII expressing clones in
a similar way. Taken together, we can conclude that expression of
TbRII in VMRC-LCD cells restore tumour suppressor function of
TGF-b.
Stable expression of TbRII decreases tumorigenicity of
VMRC-LCD cells
Loss of TGF-b signalling in human tumours is believed to be
critical in carcinogenesis. Anchorage-independent growth in
semisolid medium and the formation of xenografts in immuno-
compromised mice are generally considered to be read-outs for
assessing the tumorigenicity of human cells. To assess the effect of
TbRII expression on the malignant properties of VMRC-LCD cells,
we compared the ability of the control and TbRII stable cells to
form colonies in soft agarose. Control clones and TbRII stable
clones were tested for growth in soft agarose in 35mm culture
plates at 5 10
4cellswell
 1. After 2 weeks of incubation, colonies
were counted by automated colony counter. Significant reduction
in colony formation (both size and number) was observed in
TbRII stable clones when compared with parental and vector cells
(Figure 7A). These data suggest that stable expression of TbRII
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Figure 6 Quantitative cell death ELISA. Parental, vector control, and
TbRII stable clones were serum starved and treated with either TGF-b1( 5
or 10ngml
 1)o r1mM sodium butyrate for 24h in serum-free media. Cell
lysates were analysed by cell death ELISA as described in Materials and
methods. Individual data point is a representative of the mean7s.d. of
three individual measurements. Each experiment was repeated three times
with similar results. *Po0.0008, **Po0.0001 for all groups in a linear
mixed effect model on the log-transformed data.
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Figure 7 Stable expression of TbRII decreases tumorigenicity. (A)
Restoration of TbRII reduces anchorage-independent growth in VMRC-
LCD cells. Parental, vector control, and TbRII stable clones were plated in
soft agarose and incubated for 2 weeks. Colonies were counted by
automated colony counter and the data are representative of the
mean7s.d. of three values determined from individual plates. *Po0.005
for all groups was compared to control by Wilcoxon test. (B) Xenograft
growth curves of parental, vector control, and TbRII stable clones. Cells
(5 10
6) from each pool were subcutaneously injected to the athymic
nude mice. Tumours were measured externally on the indicated days in
two dimensions using slide calipers. Tumour volume was determined from
the equation: V¼(L W
2) 0.5, where L is length and W is width of the
tumour. Each data point represents a mean volume7s.e. of six tumours for
each group. *Po0.05 for all groups was compared to control by Wilcoxon
test.
Role of TGF-b in lung cancer
G Anumanthan et al
1164
British Journal of Cancer (2005) 93(10), 1157–1167 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sdecreases the anchorage-independent growth of VMRC-LCD cells.
Reduction in cloning efficiency in soft agarose suggested that
restoration of TGF-b sensitivity might also render VMRC-LCD
cells less tumorigenic. To test this hypothesis, we injected
exponentially growing cells from parental, vector control and
TbRII stable clones (5 l0
6) subcutaneously in athymic nude mice
and followed the progression of xenograft formation. Clones stably
expressing TbRII consistently formed smaller tumours compared
to tumours arising from parental and vector cells (Figure 7B).
tumours formed from parental and vector control cells grew
substantially faster. Together, these results suggest that over-
expression of TbRII in a TGF-b-resistant lung cancer cell line
restored TGF-b sensitivity. It is possible that the unresponsiveness
to TGF-b response in VMRC-LCD cells is merely due to lack of
TbRII expression and restoration of TbRII alone might restore
TGF-b tumour suppressor function.
DISCUSSION
The malignant transformation in several types of cancer, including
lung cancer, results in a loss of tumour suppressor effects of TGF-
b. Loss of TGF-b response has been shown to be associated with
tumour development and/or tumour progression in a number of
cancer cell lines (Masui et al, 1986; Arteaga et al, 1988; Kimchi
et al, 1988; Hoosein et al, 1993; Moustakas et al, 1993). However,
resistance to TGF-b in cancer may occur through several
mechanisms such as reduced expression of TbRI and/or TbRII,
mutations or functional inactivation of TbRII, inactivating
mutations in Smad2 and Smad4 and overexpression of inhibitory
proteins including Smad7 (Kleeff et al, 1999; Halder et al, 2005). In
addition, increased production of TGF-b by cancer cells during
tumour progression favours tumour growth, angiogenesis, and
metastasis. Reduced expression of TbRII has been implicated as a
mechanism for TGF-b resistance in both NSCLC and small-cell
lung cancer (SCLC). A recent report has suggested that tumours of
lung adenocarcinoma from nonsmokers show reduced expression
of TbRII (Powell et al, 2003). In the present study, analyses of RNA
and protein from lung tumours demonstrate that TbRII expression
is reduced or lost in 80% of squamous cell carcinoma, 42% of
adenocarcinoma and 72% of large cell carcinoma in comparison to
nontumour lesions. We have observed that stable expression of
TbRII restores TGF-b-induced transcription, growth inhibition
and apoptosis in a lung adenocarcinoma cell line lacking TbRII. As
a result these cells become less tumorigenic as determined by soft-
agar assay and tumour xenograft studies. These studies suggest
that impairment of TGF-b signalling through the loss of TbRII is
involved in lung tumour progression.
Cell growth is modulated by positive and negative signals, and
loss of negative growth constraints may contribute to oncogenic
processes. Such perturbations may occur as a consequence of the
loss of the tumour suppressor functions of TGF-b. Reduced
expression of TbRII has been reported in poorly differentiated lung
adeno, and squamous cell carcinoma by immunohistochemical
studies (Kang et al, 2000). In contrast, another study reported that
a reduced expression of TGF-b1, TbRI and TbRII correlated with
less lung tumour aggressiveness and a better prognosis (Takanami
et al, 1997). In these studies the expression levels were determined
by immunohistochemistry. However, although we have observed
reduced expression of TbRII in squamous, adeno and large cell
carcinoma by RT–PCR and Western blot, we do not find any
direct correlation between expression level and prognosis or
differentiation status. Our study is in agreement with the previous
studies with lung tumour-derived cell lines that both NSCLC and
SCLC cell lines show either no expression or weak expression of
TbRII in 65–75% cases (Hougaard et al, 1999; Osada et al, 2001).
One of the physiological roles of the TGF-b-signalling pathway
is to provide protection against malignant transformation. While
TGF-b inhibits proliferation of different normal cell types, most
tumour cells including gastric, colon, and lung carcinomas are
resistant to TGF-b-induced growth arrest. As mutations or
deletions in receptors or Smads are not common in NSCLC or
SCLC, downregulation of the expression of TbRII may be a
common mechanism for lung tumours to be resistant to TGF-b
tumour suppressor functions. To test the effect of the loss of TbRII
expression in lung cancer, we have used lung adenocarcinoma cell
line VMRC-LCD that is insensitive to growth inhibitory effects of
TGF-b and that lacks TbRII expression. Our study shows that
expression of physiological level of functional TbRII restores TGF-
b-mediated transcription by inducing complex formation between
Smad2/3 and Smad4, suggesting that TGF-b/Smad-signalling
cascade downstream of receptors is intact. A comparable level of
TGF-b-induced transcriptional response and growth inhibition has
been observed in stable TbRII-expressing VMRC-LCD clones and
A549 cells with endogenous TbRII expression. Although these two
cell lines are originally derived from lung adenocarcinoma, direct
comparison in TGF-b signalling is not possible due to different
gene expression level and mutational status. Interestingly, TbRII-
expressing clones are growth inhibited by both endogenous and
exogenous TGF-b supporting the fact that lung cancer cells could
escape from TGF-b-induced growth inhibition by losing the
expression of TbRII. In previous study, we observed that VMRC-
LCD cells produce significant amount of TGF-b (Halder et al,
2005) that may inhibit growth of these clones in an autocrine
manner after stable expression of TbRII. The effect of endogenous
TGF-b on growth inhibition in VMRC-LCD cells is further
supported by the fact that a TGF-b receptor kinase inhibitor
specifically blocks this effect in TbRII-expressing clones. Although
TGF-b is known to be a potent growth inhibitor, it also functions
as an inducer of apoptosis. Stable expression of TbRII in these
cells restores TGF-b-induced apoptosis. It is possible that loss of
TGF-b-mediated apoptosis by reduced expression of TbRII may
be involved in the lung tumour progression. The increased
expression and activation of TGF-b by tumour cells may induce
pro-oncogenic effects that result in the progression of epithelial
tumours to the metastatic stage. However, after restoration of
TGF-b signalling in VMRC-LCD cells we do not observe any
change in the tumour-promoting effects of TGF-b including cell
motility, epithelial to mesenchymal transition, migration and
invasion (data not shown).
Loss of TGF-b response has been reported to be associated with
tumour development and/or progression in a number of cancer
cell lines. While some TGF-b-resistant cancer cell lines have been
shown to retain intact TGF-b receptors, majority of the cancer cell
lines show the loss of TGF-b tumour suppressor function that
could be associated with reduced expression of TGF-b receptors.
We have observed reduced cloning efficiency in soft-agar assay by
TbRII-expressing clones. In addition, stable expression of TbRII in
these cells decreases tumorigenicity in vivo. Therefore, loss of
TbRII expression leads to the generation of an aggressive
phenotype in lung carcinoma cells and restoration of TGF-b-
induced tumour suppressor function through the expression of
TbRII plays an important role in decreasing tumorigenicity.
In conclusion, these data support the notion that TGF-b type II
receptor plays a critical role in cell proliferation and lung
carcinogenesis. The defective expression of TbRII may provide
an important molecular mechanism in explaining unresponsive-
ness to TGF-b in lung carcinomas. Stable expression of TbRII
alone plays an important functional role in reducing tumour
growth by restoring TGF-b-mediated tumour suppressor functions
in lung tumour cells that lack TbRII. Our study showed that
overexpression of TbRII restored TGF-b sensitivity and reduced
the tumour growth. As majority of NSCLC and SCLC cell lines,
that are not responsive to TGF-b-induced growth inhibition,
show weak or no expression of TbRII (Hougaard et al, 1999;
Osada et al, 2001), restoration of TGF-b signalling through the
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therapeutic intervention.
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